导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 27.39% | 191/4773 |
| 近一周 | 2.24% | 126/5465 |
| 近一月 | -2.99% | 2072/5421 |
| 近一季 | -5.35% | 2048/5231 |
| 近半年 | 18.14% | 276/4920 |
| 近一年 | 32.97% | 189/4394 |
| 近两年 | 181.70% | 113/2954 |
| 近三年 | 114.67% | 117/2253 |
| 成立以来 | 54.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.06% 3020/4961 |
74.06% 224/5312 |
- - |
- - |
| 2025 | 52.42% 409/4813 |
8.97% 423/3635 |
1.51% 2299/4076 |
40.52% 752/4524 |
-1.94% 3040/4813 |
| 2024 | 11.87% 1293/3463 |
-10.75% 2375/2808 |
-2.83% 1261/3014 |
17.12% 1272/3129 |
10.15% 288/3463 |
| 2023 | 2.72% 306/2656 |
27.14% 87/2280 |
-7.89% 1929/2385 |
-11.32% 2052/2515 |
-1.09% 284/2655 |
| 2022 | -30.61% 1637/2207 |
-23.03% 1722/1919 |
-0.13% 1597/2016 |
-13.79% 973/2113 |
4.70% 519/2208 |
| 2021 | 15.78% 294/1822 |
-9.21% 1105/1255 |
19.05% 166/1330 |
-3.87% 662/1466 |
11.43% 86/1822 |
| 2020 | 7.33% 866/1250 |
-0.37% 184/1028 |
20.34% 274/1067 |
-2.98% 1082/1164 |
-7.73% 1158/1184 |
| 2019 | 74.20% 26/1092 |
49.86% 7/754 |
-10.01% 709/804 |
17.98% 11/850 |
9.48% 223/918 |
| 2018 | -32.32% 529/834 |
- - |
- - |
- - |
-15.28% 601/691 |
| 2017 | 1.06% 459/714 |
- - |
- - |
- - |
- - |
| 2016 | -22.75% 460/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证500信息技术ETF VS. 长安沪深300非周期A(740101) |